Effects of Pentoxifylline on Severe Intermittent Claudication

Reich, Theobald; Gilings, Dennis
September 1987
Angiology;Sep1987, Vol. 38 Issue 9, p651
Academic Journal
Pentoxifylline has been shown to improve treadmill walking distances under blinded, controlled conditions in patients with intermittent claudication. From the pooled data of a blinded, controlled, randomized, multicenter trial, the data from all enrolled patients with severe claudication (< 70 m on treadmill at baseline) were evaluated. The treadmill data from these more severely ill patients were analyzed separately as a “severe subset” (placebo n = 17; pentoxifylline n=21). No differences between the two treatment groups were observed in demography, history, or baseline treadmill walking distances. The initial claudication distance (ICD) improved 68% over baseline with pentoxifylline and 12% with placebo (p=.012) after twenty-four weeks of treatment. A new, derived efficacy variable was developed, “minimum distance walked,” which tended to minimize psychological effects on treadmill performance. Over sixteen to twenty-four weeks of treatment, the pentoxifylline group improved 49% over baseline and the placebo group 3% (p=.019), when the “minimum distance walked” measurement was used. In this controlled trial the subset of patients with severe intermittent claudication benefited from pentoxifylline therapy.


Related Articles

  • Treatment of intermittent claudication. Karthikeyan, G.; Eikelboom, John W. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/21/2009, p671 

    The authors reflect on methods which are used to treat intermittent claudication. They suggest that any methods that are used should improve the patient's symptoms and decrease the risk of cardiovascular problems. They argue that the most important goal of medical treatment in patients with...

  • Pentoxifylline for Intermittent Claudication. Ernst, E. // Angiology;May1994, Vol. 45 Issue 5, p339 

    Pentoxifylline was first introduced in Germany twenty years ago. Today it is the best researched oral drug for intermittent claudication. A total of seventeen placebo-controlled trials could be retrieved from the world literature. The majority of these studies show that pentoxifylline will...

  • Comparison of Safety and Efficacy of Buflomedil and Naftidrofuryl in the Treatment of Intermittent Claudication. Rosas, Guillermo; Cerdeyra, Cristina; Lucas, Miguel A.; Parano, Jorge R.; Villa, Juan J. // Angiology;May1981, Vol. 32 Issue 5, p291 

    In a group of 58 patients with peripheral arteriopathies, we have studied efficacy and safety of buflomedil hydrochloride and naftidrofuryl. Both drugs have been shown to have vasoactive properties evaluated through walking capacity and time of hyperemia. According to our results, buflomedil is...

  • Comparative Evaluation of Pentoxifylline, Buflomedil, and Nifedipine in the Treatment of Intermittent Claudication of the Lower Limbs. Chacón-Quevedo, A.; Eguaras, M. G.; Calleja, F.; Garcia, M. A.; Roman, M.; Casares, J.; Muñoz, I.; Concha, M. // Angiology;Jul1994, Vol. 45 Issue 7, p647 

    In the light of the current controversy surrounding the use of hemorheologic and vasodilator drugs in the treatment of peripheral arteriosclerosis, a comparative study was designed in order to evaluate the efficacy of pentoxifylline, buflomedil, and nifedipine in 45 patients with peripheral...

  • Naftidrofuryl: A Review of its Use in the Treatment of Intermittent Claudication. Goldsmith, David R.; Wellington, Keri // Drugs & Aging;2005, Vol. 22 Issue 11, p967 

    Naftidrofuryl (Praxilene®) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief. However, earlier trials had inconsistencies in design and the clinical relevance of the treatment...

  • Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies. Mangiafico, Roberto A.; Fiore, Carmelo E. // Current Vascular Pharmacology;Jul2009, Vol. 7 Issue 3, p394 

    Lower extremity peripheral arterial disease (PAD) is a manifestation of atherosclerosis, with a prevalence ranging from 4% to 12% in the adult population and increasing up to 20% in older individuals. Intermittent claudication (IC) may markedly impair walking ability, overall functional status...

  • Photoplethysmographic Documentation of Improved Microcirculation After Pentoxifylline Therapy. Roeren, Thomas; LeVeen, Robert F.; Nugent, Loree // Angiology;Nov1988, Vol. 39 Issue 11, p929 

    Pentoxifylline is the prototype of a new class of drugs that improve peripheral blood flow mainly by increasing red blood cell flexibility. Few studies have been performed to objectively evaluate the effect of the drug in a routine clinical setting. In 11 patients with intermittent claudication,...

  • THERAPY IN INTERMITTENT CLAUDICATION. Pomeranze, Julius; Gadek, Rymond J.; Pitman, Ernest R.; Scherl, Siegfried // Angiology;Jun1955, Vol. 6 Issue 3, p271 

    A pharmacologic evaluation of Arlidin indicates strong muscle vasodilator activity and an adequate increase in cardiac output. Clinical evaluation indicates excellent results in relief from intermittent claudication. The over-all therapy of peripheral vascular diseases and its associated spasm...

  • Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication? Weismantel, David // Journal of Family Practice;Feb2001, Vol. 50 Issue 2, p181 

    This article presents a study which examined the effectiveness of cilostazol over pentoxifylline in the treatment of symptoms of intermittent claudication. The study population is composed of patients with stable moderate to severe symptoms of intermittent claudication and confirmed peripheral...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics